Targeting MAP3K19 both in vitro and in vivo markedly altered IPF fibroblast to myofibroblast differentiation and the maintenance of pulmonary fibrosis in C.B-17SCID/bg humanized with IPF fibroblasts. Here, MAP3K19 is linked to idiopathic pulmonary fibrosis.